Results 121 to 130 of about 32,388 (251)

Safety of Fecal Microbiota Transplantation in Children: A Single-Center Experience. [PDF]

Children (Basel)
Varnas D, Urbonas V.
europepmc   +1 more source

Diet–Microbiome–Immune Interactions at the Gut Mucosa in Food Allergy: Mechanisms, Gaps, and Therapeutic Implications

Allergy, EarlyView.
ABSTRACT Mucosal surfaces are sites of highly dynamic interactions among epithelial and immune cells, environmental exposures, particularly dietary inputs, and the diverse microbial communities and their metabolites. These elements continually influence each other to maintain homeostasis and ensure appropriate immune discrimination between pathogens ...
Clara Delaroque, Liam O'Mahony, Inge Kortekaas Krohn, Charlotte G. Mortz, Markus Ollert, Mahesh S. Desai   +5 more
wiley   +1 more source

The selection of matching donors for patients in fecal microbiota transplantation. [PDF]

Front Microbiol
Qian X, Wu Y, Wang W, Shao H, Xu Z.
europepmc   +1 more source

Dietary Habits and Atopic Dermatitis Significantly Influence the Fecal Microbiome

Allergy, EarlyView.
Atopic dermatitis, dietary habits, sex, and BMI significantly influenced the fecal microbiome composition. On the species level, Faecalibacterium taiwanense was more abundant in atopic dermatitis, and Vescimonas sp000435555 was more abundant in the control population. On the genus level, CAG‐302 (NCBI: Clostridium) was more abundant in controls.
Danielle Fehr, Nicole Flack, Gloria Masenga, Nelson Mosha, Nick Li, Anna White, George Semango, Meike Distler, Claudia Lang, Felix Grimm, Michael Scharl, Daudi Mavura, John Elisante Masenga, Peter Schmid‐Grendelmeier, Marie‐Charlotte Brüggen   +14 more
wiley   +1 more source

Cohesive modules of engraftment in fecal microbiota transplantation. [PDF]

iScience
Rashidi A, Minot SS, Lee SJ, Hill GR, Podlesny D.   +4 more
europepmc   +1 more source

Review Article: Immune Effector Cell‐Mediated Enterocolitis Following CAR‐T Cell Therapy—Clinical Features, Pathophysiology and Management

Alimentary Pharmacology &Therapeutics, EarlyView.
Immune effector cell‐mediated enterocolitis is an emerging complication of CAR‐T therapy. This review summarizes its epidemiology, pathophysiology, diagnosis, endoscopic and histopathologic features, and evidence‐based management, emphasizing early recognition, multidisciplinary intervention, and step‐up therapy.
John A. Damianos, Yi Lin, Zongming Eric Chen, Kenneth J. C. Lim, Navreet M. Chowla   +4 more
wiley   +1 more source

Fecal microbiota transplantation for marked colonic dilatation. [PDF]

Korean J Intern Med
Cho E, Lee JH, Hong JT, Kwon KS, Shin YW.   +4 more
europepmc   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

A Refined Method for Fecal Microbiota Transplantation Using Nutella. [PDF]

Clin Transl Sci
Henriksen IW, Hansen CHF, Koch J, Sørensen DB, Nielsen DS, Bartholdy C, Hansen AK.   +6 more
europepmc   +1 more source

Novel therapeutic targets for chronic visceral pain in gastrointestinal disorders

British Journal of Pharmacology, EarlyView.
Chronic visceral pain imposes a major clinical challenge in gastroenterology and beyond, profoundly impacting patients' quality of life. However, limited understanding of its complex, multifaceted pathophysiology, encompassing both peripheral and central mechanisms, continues to impede the development of effective management strategies.
Fleur Veldman, Christopher J. Black, Andrea Shin, Daniel Keszthelyi   +3 more
wiley   +1 more source